Giovanna Catania

Mantova, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.

Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.

Journal: Ocular immunology and inflammation

Published: February 03, 2022

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?

Journal: Oncology

Published: October 04, 2021

Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study.

Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study.

Journal: Cancers

Published: February 15, 2021

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 23, 2020

Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

Journal: Future oncology (London, England)

Published: June 06, 2020

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.

Journal: NPJ breast cancer

Published: November 11, 2019

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.

Journal: Cancers

Published: September 25, 2019

LHRH analogs: current role in early and advanced breast cancer treatment of premenopausal patients.

LHRH analogs: current role in early and advanced breast cancer treatment of premenopausal patients.

Journal: Recenti progressi in medicina

Published: August 06, 2019

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Journal: Oncology

Published: July 25, 2018

Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study.

Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study.

Journal: Journal of breath research

Published: July 04, 2018

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: April 30, 2018

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

Journal: Oncology

Published: October 09, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026